Compositions and methods for modulating c-kit and PDGFR receptors
    36.
    发明授权
    Compositions and methods for modulating c-kit and PDGFR receptors 失效
    用于调节c-kit和PDGFR受体的组合物和方法

    公开(公告)号:US08106068B2

    公开(公告)日:2012-01-31

    申请号:US12629665

    申请日:2009-12-02

    CPC分类号: C07D471/04

    摘要: The invention provides compounds of Formula (2), and pharmaceutical compositions thereof, wherein R1, R2, R3, R4 and L are as described herein; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.

    摘要翻译: 本发明提供式(2)的化合物及其药物组合物,其中R1,R2,R3,R4和L如本文所述; 以及使用这些化合物治疗,改善或预防与异常或失调的激酶活性相关的病症的方法。 在一些实施方案中,本发明提供了使用这些化合物治疗,改善或预防涉及c-kit,PDGFRα,PDGFR和bgr,CSF1R,Abl,BCR-Abl,CSK,JNK1,JNK2,p38异常活化的疾病或病症的方法 ,p70S6K,TGF-bgr,SRC,EGFR,trkB,FGFR3,FLT3,Fes,Lck,Syk,RAF,MKK4,MKK6,SAPK2&bgr,BRK,KDR,c-raf或b-raf激酶或其突变形式。